Beginning Next Week: InsideCounsel will become part of Corporate Counsel. Bringing these two industry-leading websites together will now give you comprehensive coverage of the full spectrum of issues affecting today's General Counsel at companies of all sizes. You will continue to receive expert analysis on key issues including corporate litigation, labor developments, tech initiatives and intellectual property, as well as Women, Influence & Power in Law (WIPL) professional development content. Plus we'll be serving all ALM legal publications from one interconnected platform, powered by Law.com, giving you easy access to additional relevant content from other InsideCounsel sister publications.

To prevent a disruption in service, you will be automatically redirected to the new site next week. Thank you for being a valued InsideCounsel reader!

X

Pay-for-delay deals rise

Report finds increase in pacts among drug companies despite FTC’s efforts to reduce them

A new Federal Trade Commission (FTC) report found an increase in pay-for-delay deals, in which brand-name pharmaceutical companies settle patent litigation with generic-drug companies by reaching agreements that delay the release of cheaper drugs to market.

According to the report, drug companies made 40 pay-for-delay agreements involving 31 different brand-name drugs with combined sales of more than $8.3 million in the 2012 fiscal year. In nearly half of the deals, the brand-name companies agreed not to market their generics that would compete with the generic-drug companies’ products as long as the generic-drug companies promised to delay production of their drugs.

The number of pay-for-delay deals that companies made in 2012, which is 12 more than they made in fiscal year 2011, is the largest since the FTC started collecting such data in 2003.

The increase in pay-for-delay agreements occurred despite the FTC’s efforts to quash such deals. The agency has challenged several settlements in court, claiming they violate antitrust laws.

“This year’s report makes it clear that the problem of pay-for-delay is getting worse, not better,” FTC Chairman Jon Leibowitz said in a statement. “Until this issue is resolved, we will all suffer the consequences of delayed generic entry—higher prices for consumers, businesses and the U.S. taxpayer.”

Read Bloomberg and Thomson Reuters for more about the FTC’s findings.

For more InsideCounsel coverage of pay-for-delay deals, read:

Circuit split reignites debate over reverse payments

Supreme Court may decide whether “reverse payment” settlements violate antitrust law

Court Denies En Banc Review in "Pay for Delay" Generic Drug Case

Pay for Delay

Ashley Post

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.